Estrella Immunopharma, Inc. (ESLA) quarterly cash flow statement — complete operating, investing & financing history
| Cash from Operations | -6.7M | -177.49K | -727.33K | -414.88K | -465.98K | -896.07K | -2.22M | -291.51K | -4.23M | -11.27M | -275.19K | -212.67K |
| Operating CF Margin % | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating CF Growth % | -1337.4% | 80.19% | 67.2% | -42.32% | 89% | 92.05% | -705.79% | -37.08% | -1435.86% | -10313.48% | 46.37% | 77.05% |
| Net Income | -2.29M | -613.17K | -4.8M | -5.54M | -2.1M | -1.05M | -3.38M | -3.95M | -469.53K | -1.02M | -1.87M | -76K |
| Depreciation & Amortization | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 0 | 148.36K | 152.42K | 159.1K | 159.09K | 0 | 0 | 0 | 0 | 0 | 1.19M | 0 |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 598 |
| Other Non-Cash Items | 255.34K | -28.85K | 67.04K | 0 | 0 | 432.26K | 0 | 0 | 77.08K | 9.26M | 1.19M | -114.31K |
| Working Capital Changes | -4.66M | 316.18K | 3.85M | 4.97M | 1.48M | -278.03K | 1.16M | 3.66M | -3.77M | -10.25M | 400.65K | -22.95K |
| Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | -539.83K | 549.15K | -2.52K | -5.83K | 9.55K | 0 | 5K | 0 | -77.08K | -9.26M | 4.5K | 0 |
| Cash from Investing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5.07M | -112.3K | 21.43K |
| Capital Expenditures | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 0 | 0 | 0 | 0 |
| CapEx % of Revenue | - | - | - | - | - | - | - | - | - | - | - | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5.07M | -112.3K | 0 |
| Cash from Financing | 7.24M | -64.82K | 1.04M | 1.31M | -29.46K | 15.48K | -150.47K | -270.35K | -84.09K | -6.9M | 20.05M | 196.53K |
| Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -10M | 0 | -300K | 10.3M | 196.53K |
| Equity Issued (Net) | 8M | 0 | 1.05M | 1.35M | -29.46K | 15.48K | 0 | 0 | -84.09K | -5.07M | 19.02M | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | -29.46K | -64.01K | -150.47K | -270.35K | -84.09K | -5.07M | 0 | 0 |
| Other Financing | -758.88K | -64.82K | -12.65K | -40K | 0 | 0 | -150.47K | 9.73M | 0 | -1.53M | -9.27M | 0 |
| Net Change in Cash | 543.1K | -242.31K | 310.02K | 895.12K | -495.44K | -880.59K | -2.37M | -561.86K | -4.32M | -13.09M | 19.66M | 5.3K |
| Free Cash Flow | -6.7M | -177.49K | -727.33K | -414.88K | -465.98K | -896.07K | -2.22M | -291.51K | -4.23M | -11.27M | -275.19K | -212.67K |
| FCF Margin % | - | - | - | - | - | - | - | - | - | - | - | - |
| FCF Growth % | -1337.4% | 80.19% | 67.2% | -42.32% | 89% | 92.05% | -705.79% | -37.07% | -1435.86% | -10313.48% | 46.37% | 77.05% |
| FCF per Share | -0.16 | -0.00 | -0.02 | -0.01 | -0.01 | -0.02 | -0.06 | -0.01 | -0.12 | -0.32 | -0.26 | -0.09 |
| FCF Conversion (FCF/Net Income) | 2.92x | 0.29x | 0.15x | 0.07x | 0.22x | 0.85x | 0.66x | 0.07x | 9.02x | 11.04x | 0.15x | 2.80x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | -913 | 0 | 900 | 13 | 0 | 0 | 1.6K | 0 | 0 | 0 | 0 |